ABOUT / 08
About Wolverine Medicinal
An independent editorial project that documents the published research on the BPC-157 TB-500 blend — read like a specification, cited like a reference.
What This Site Is
Wolverine Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 blend. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built as a documentation reference: a near-monochrome, type-and-whitespace surface where every machine identifier — a sequence, a molecular weight, a PubMed ID — sits in a monospace data channel, and every finding is tagged to the constituent it belongs to. The design is deliberate. The honest story of this blend is sober — two separately characterized peptides, an overwhelmingly preclinical record, no controlled combination trial, and Category 2 regulatory status — and the surface is built to read that way rather than to sell.
On the Word "Medicinal"
The "medicinal" in the domain name is editorial framing, not a claim about services. It signals the register this reference occupies — what the blend's constituents are studied for, and how compounded access and regulatory status actually work — not a clinic, a dispensary, or a prescription service. We do not offer treatment, consultation, or prescription services, and we describe no human dose anywhere on the site.
Everything here is third-person and study-attributed. Where the literature is precise, we state the number and cite it. Where it is silent — and for the BPC-157 plus TB-500 combination it is largely silent — we say so plainly. That distinction is the whole editorial method.
How We Handle Sources
Every quantitative claim on the site maps to a numbered citation on the BPC-157 and TB-500 research findings reference list — a DOI or PubMed link for each peer-reviewed study, and the FDA source page for each regulatory fact. We do not extrapolate beyond what a study measured, and we do not present community protocols, fixed-ratio vials, or "loading" schedules as validated dosing.
We keep the two constituents on separate channels because conflating them is the most common error in writing about this blend: most "TB-500" efficacy data were generated with full-length Thymosin Beta-4, not the Ac-LKKTETQ heptapeptide, and we flag that gap wherever it bears on a claim.